1. Information Pathway and Eligibility Criteria

2. Information pathway
We anticipate that all woman when they are admitted to hospital in labour will already be aware of the trial
The ANODE Antenatal Information Sheet should be given to women antenatally and when entering delivery suite in labour
Areas to introduce this Antenatal Information Sheet include, anomaly scan clinics, antenatal classes, GTT clinics and during induction of Labour
Display the Antenatal Poster within these areas
V6.0 17/01/17

3. Information pathway
In addition to the ANODE Antenatal Information Sheet there are two versions of the ANODE Participant Information Leaflet
These leaflets should not be given to women until an Instrumental Delivery is confirmed
Leaflet A should be given to women who have no time constraint and are considered able to give written consent.
Leaflet B should be given to women who have given verbal consent and have received the trial intervention prior to obtaining written consent
V6.0 17/01/17

4. Who can take part? Inclusion Criteria
Women aged 16 years or above, willing and able to give informed consent
Women who have had an operative vaginal delivery at 36+0 weeks or greater gestation
V6.0 17/01/17

5. Who can take part? Exclusion Criteria
Women may not enter the trial if ANY of the following apply:
Clinical indication for ongoing antibiotic administration post-delivery e.g. due to confirmed antenatal infection or 3rd of 4th degree tears
Note that receiving antenatal antibiotics e.g. for maternal Group B Streptococcal carriage or prolonged rupture of membranes, is not a reason for exclusion if there is no indication for ongoing antibiotic prescription post-delivery.
Known allergy to penicillin or to any of the components of co-amoxiclav, as documented in hospital notes  
History of anaphylaxis (a severe hypersensitivity reaction) to another B-lactam agent (e.g. cephalosporin, carbapenem or monobactam), as documented in hospital notes  
V6.0 17/01/17

6. Intervention arm/Control arm
Women will be randomised to either the active intervention arm or the placebo control arm of the trial via the taking of a sequentially numbered indistinguishable sealed box
Those in the active intervention arm will receive a single dose of intravenous co-amoxiclav (1000 mg amoxicillin/200 mg clavulanic acid)
Those in the placebo control arm will receive a single dose of intravenous normal saline (0.9% normal saline)
V6.0 17/01/17